A low FODMAP diet for diarrhoea predominant functional gastrointestinal disorders in pancreatic and mid-gut neuroendocrine tumour patients

The Royal Free Hospital (UK)0 个研究点目标入组 40 人开始时间: 2015年12月11日最近更新: 2021年5月3日

适应症

试验速览

暂无简介。

•Adult patients who have diarrhoea predominant functional gastrointestinal disorder in the following susceptible groups:
•1. Non-functioning small bowel NETs who have never had any treatment
•2. Functioning small bowel NET patients on symptom controlling treatment which is not thought to be causing diarrhoea. These patients should be on a stable dose of somatostatin analogues and/or pancreatic enzyme replacement therapy for at least 3 months
•3. Small bowel NET patients who are at least 3 months post intestinal surgery/injury/radiotherapy, chemotherapy PRRT, molecular targeted therapy (sunitunib, everolimus) or interferon
•4. Pancreatic NET patients who have undergone the whipples operation with small bowel involvement and are at least 3 months post surgery
•5. Smaller pancreatic functioning NET patients who have stable disease on somatostatin analogues

•Patients must NOT have:
•1. Diarrhoea directly related to uncontrolled hormone secretion of the tumour
•2. Steatorrhoea due to insufficient pancreatic enzyme use (starting dose is 25,000 units lipase per meal, titrated up to 75,000-80,000 units lipase per meal)
•3. Bile salt malabsorption
•4. Short bowel syndrome
•5. Any gastrointestinal disease other than a NET
•6. Have constipation as the predominant symptom
•7. Bacterial overgrowth in the past 4 weeks
•8. Been on antibiotics in the past 4 weeks
•9. Been on any lactulose, prebiotic or probiotic in the past 4 weeks
•10. Had changes to any IBS medication in the past 4 weeks
•11. Have had bowel preparation or investigative procedures in the past 4 weeks
•12. Be pregnant or lactating
•13. Diabetes, current eating disorders or psychiatric illness
•14. A poor level of English skills

发起方

The Royal Free Hospital (UK)